Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports

12-28-2018

Implantable biomaterials to provide local
immunotherapy following surgical resection.
Michael J Gough
Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA

Jason R Baird
Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA

R Bryan Bell
Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Oncology Commons, and the Surgery Commons
Recommended Citation
Gough, Michael J; Baird, Jason R; and Bell, R Bryan, "Implantable biomaterials to provide local immunotherapy following surgical
resection." (2018). Articles, Abstracts, and Reports. 1065.
https://digitalcommons.psjhealth.org/publications/1065

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles,
Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.

www.oncotarget.com

Oncotarget, 2018, Vol. 9, (No. 102), pp: 37612-37613
Editorial

Implantable biomaterials to provide local immunotherapy
following surgical resection
Michael J. Gough, Jason R. Baird and R. Bryan Bell
Surgical extirpation of the primary tumor and
draining lymph nodes followed by histopathologic riskadapted adjuvant radiation or chemoradiation remains
the standard of care for most patients with Head and
Neck Squamous Cell Carcinoma (HNSCC). However,
non-viral associated (HPV-) HNSCC is characterized by
a high rate of therapeutic resistance: approximately 3050% of these patients have local or distant recurrence
following conventional treatment. Furthermore, there is
some evidence to suggest that extirpative surgery itself is
immunosuppressive and may promote cancer progression
[1]. Identification and successful integration of novel
immunotherapy into existing treatment paradigms of
surgery and radiation for HNSCC is an evolving treatment
approach that has the potential to overcome suppressive
mechanisms within the tumor and lead to enhanced
survival and decreased morbidity for patients with
locally advanced or recurrent HNSCC [2]. Our research
in preclinical models has shown that immune responses
play an important role in local tumor control following
surgical resection [3], and there is increasing evidence that
the addition of local or systemic immunotherapy before
(neoadjuvant) or after (adjuvant) surgery may enhance
survival [3-5].
The tumor environment is the primary target
site for anti-tumor immune responses, but commonly
evolves during malignant progression to include a range
of suppressive mechanisms. Information obtained from
the surgical resection specimen may be leveraged to
tailor immunotherapy interventions targeting the surgical
site to eliminate minimal residual disease and minimize
recurrence. Biomaterial platforms can be constructed to
provide a local delivery system for such immunotherapies,
which can be applied to the resection bed at the time of
surgery, and be utilized to enhance the effectiveness
of surgery. We recently demonstrated that cyclic-dinucleotides (CDN), which are ligands of STimulator of
INterferon Genes (STING), incorporated into a simple
biomaterial and placed into the resection cavity were
able to eliminate residual disease in preclinical models of
HNSCC [4]. CDN are naturally generated following cGAS
recognition of cytoplasmic DNA from endogenous sources
or following intracellular infection, and CDN binding to
STING results in activation of IRF3 and transcription of
type I IFN. STING therefore forms part of an endogenous
nucleic acid sensing mechanism that can be exploited for
cancer therapy [6]. Initial studies using direct injection
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of CDN into the tumor resulted in CD8 T cell-mediated
clearance of cancer cells [7]. We found that application of
STING in a biomaterial to the resection cavity prevented
recurrence of residual disease [4], consistent with other
investigators [5]. The mechanism required host responses
to inflammatory cytokines and as with direct injection, the
final tumor clearance was mediated by CD8 T cells [4, 5].
These data suggest that biomaterial platforms present an
opportunity to orchestrate local immune responses in the
surgical site to prevent tumor recurrence. While there is a
clear rationale to apply this to prevent HNSCC recurrence,
this approach is equally applicable to a range of other
malignancies.
HNSCC patients respond variably to conventional
cancer therapies, in part because of their differing antitumor immune status [8, 9]. Similarly, not all patients
respond to immunotherapy combinations, likely for
similar reasons. To understand this variability, we
developed an ‘explant assay’ using fragments of tumor
stimulated ex vivo with innate adjuvants [4]. This can
also be achieved using single cell suspensions of tumorinfiltrating cells [10], but the explant approach has the

Figure 1: The combination of implantable biomaterials
together with ex vivo analysis of the tumor immune
biology permits personalization of surgical
immunotherapy to prevent tumor recurrence.
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advantage of preserving the geographic relationship
between the different cell types and their regulatory
networks. Importantly, this approach highlighted the
diversity of responses to the same agents between different
patient tumors. Using this approach, we noted IL-10
production in murine tumors that responded poorly to
STING ligands, and that the addition of antibodies that
block IL-10 improved the response in these tumors [4]. In
this way, analysis of the excised tumor for its biological
response to immunotherapy may permit personalization
and expand the in vivo response rate.
Immunotherapy for cancer is no longer a theory, but
along with all other cancer therapies, we need to know
why some people respond and others do not. If tumor
explants provide an authentic guide to the local response to
immunotherapy agents, they can permit rapid screening of
patient tumors against multiple agents. More importantly,
they may help provide a mechanistic understanding of
the key cell types, differentiation status, and geographical
relationships that dictate the response to immunotherapy.
Together, ex vivo analysis of the biological response of the
tumor may permit personalization of immunotherapy to
generate cures in patients that are currently unresponsive.
Finally, understanding the key immunological processes
that need to occur at the resection site to control residual
disease has the potential to expand the role of surgery
beyond cytoreduction and develop it as an immunological
event.
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